CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
KNS-760704drug
Likely dose
KNS-760704 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00931944
NCT00931944Phase 2Completed
CompareCT.gov

An Open-Label, Safety and Tolerability, Study Evaluating KNS-760704 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Knopp Biosciences·interventional·Posted Jul 2, 2009·Updated Aug 16, 2021

In Brief

A Phase 2 clinical trial evaluating KNS-760704 for Amyotrophic Lateral Sclerosis. Completed, enrolled 74 participants across 19 sites.

Detailed Summary

This is an open-label, multi-center study designed to extend the evaluation of the safety, tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2, 2009
Enrollment StartJul 1, 2009
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 17 years ago

Interventions

KNS-760704drug

150 mg Q12H KNS-760704 given orally (300 mg total daily dose)